Cynata completes enrollment in phase 2 trial for graft disease treatment

Sun, 14 Dec 2025 19:22:45 -0500

Cynata Therapeutics Limited (ASX: CYP) announced it has completed patient enrollment in its Phase 2 clinical trial of CYP-001 for treating acute graft versus host disease.

The study enrolled 65 participants across clinical centers in the United States, Europe and Australia. Each participant was randomized to receive either steroids plus CYP-001 or steroids plus placebo.

The trial includes a 100-day primary evaluation period expected to conclude in March 2026, with results anticipated around June 2026. The primary endpoint measures Overall Response Rate at Day 28.

Acute graft versus host disease is a complication of bone marrow transplantation where donor immune cells attack recipient

Cynata completes enrollment in phase 2 trial for graft disease treatment

Sun, 14 Dec 2025 19:22:45 -0500

Cynata Therapeutics Limited (ASX: CYP) announced it has completed patient enrollment in its Phase 2 clinical trial of CYP-001 for treating acute graft versus host disease.

The trial includes a 100-day primary evaluation period expected to conclude in March 2026, with results anticipated around June 2026. The primary endpoint measures Overall Response Rate at Day 28.

Acute graft versus host disease is a complication of bone marrow transplantation where donor immune cells attack recipient

Cynata completes enrollment in phase 2 trial for graft disease treatment

Sun, 14 Dec 2025 19:22:45 -0500

Cynata Therapeutics Limited (ASX: CYP) announced it has completed patient enrollment in its Phase 2 clinical trial of CYP-001 for treating acute graft versus host disease.

The trial includes a 100-day primary evaluation period expected to conclude in March 2026, with results anticipated around June 2026. The primary endpoint measures Overall Response Rate at Day 28.

Acute graft versus host disease is a complication of bone marrow transplantation where donor immune cells attack recipient

Cynata completes enrollment in phase 2 trial for graft disease treatment

Sun, 14 Dec 2025 19:22:45 -0500

Cynata Therapeutics Limited (ASX: CYP) announced it has completed patient enrollment in its Phase 2 clinical trial of CYP-001 for treating acute graft versus host disease.

The trial includes a 100-day primary evaluation period expected to conclude in March 2026, with results anticipated around June 2026. The primary endpoint measures Overall Response Rate at Day 28.

Acute graft versus host disease is a complication of bone marrow transplantation where donor immune cells attack recipient

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Sun, 14 Dec 2025 19:22:00 -0500

Announcement Highlights:

Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
Primary evaluation period expected to complete in March 2026, with results in June 2026.
CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.

MELBOURNE, Australia, Dec. 14, 2025 /PRNewswire/ --

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Sun, 14 Dec 2025 19:22:00 -0500

Announcement Highlights:

Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
Primary evaluation period expected to complete in March 2026, with results in June 2026.
CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.

MELBOURNE, Australia, Dec. 14, 2025 /PRNewswire/ --

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Sun, 14 Dec 2025 19:22:00 -0500

Announcement Highlights:

Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
Primary evaluation period expected to complete in March 2026, with results in June 2026.
CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.

MELBOURNE, Australia, Dec. 14, 2025 /PRNewswire/ --

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Sun, 14 Dec 2025 19:22:00 -0500

Announcement Highlights:

Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
Primary evaluation period expected to complete in March 2026, with results in June 2026.
CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.

MELBOURNE, Australia, Dec. 14, 2025 /PRNewswire/ --

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Sun, 14 Dec 2025 19:22:00 -0500

Announcement Highlights:

Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
Primary evaluation period expected to complete in March 2026, with results in June 2026.
CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.

MELBOURNE, Australia, Dec. 14, 2025 /PRNewswire/ --

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Sun, 14 Dec 2025 19:22:00 -0500

Announcement Highlights:

Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
Primary evaluation period expected to complete in March 2026, with results in June 2026.
CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.

MELBOURNE, Australia, Dec. 14, 2025 /PRNewswire/ --

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Sun, 14 Dec 2025 19:22:00 -0500

Announcement Highlights:

Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
Primary evaluation period expected to complete in March 2026, with results in June 2026.
CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.

MELBOURNE, Australia, Dec. 14, 2025 /PRNewswire/ --

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Sun, 14 Dec 2025 19:22:00 -0500

Announcement Highlights:

Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
Primary evaluation period expected to complete in March 2026, with results in June 2026.
CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.

MELBOURNE, Australia, Dec. 14, 2025 /PRNewswire/ --

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

Wed, 04 Dec 2024 22:34:00 -0500

MELBOURNE, Australia, Dec. 4, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).

Key Highlights

The trial met its primary objective, with CYP-006TK found to be safe and well-tolerated – no participants withdrew from the trial due to adverse events, and no suspected serious adverse reactions were reported.
Importantly, the trial also generated positive efficacy data, indicating improved wound healing for CYP-006TK compared to the standard of

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

Wed, 04 Dec 2024 22:34:00 -0500

Key Highlights

The trial met its primary objective, with CYP-006TK found to be safe and well-tolerated – no participants withdrew from the trial due to adverse events, and no suspected serious adverse reactions were reported.
Importantly, the trial also generated positive efficacy data, indicating improved wound healing for CYP-006TK compared to the standard of

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

Wed, 04 Dec 2024 22:34:00 -0500

Key Highlights

The trial met its primary objective, with CYP-006TK found to be safe and well-tolerated – no participants withdrew from the trial due to adverse events, and no suspected serious adverse reactions were reported.
Importantly, the trial also generated positive efficacy data, indicating improved wound healing for CYP-006TK compared to the standard of

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

Wed, 04 Dec 2024 22:34:00 -0500

Key Highlights

The trial met its primary objective, with CYP-006TK found to be safe and well-tolerated – no participants withdrew from the trial due to adverse events, and no suspected serious adverse reactions were reported.
Importantly, the trial also generated positive efficacy data, indicating improved wound healing for CYP-006TK compared to the standard of

Further CYP-001 GvHD Clinical Data Published in Nature Medicine